November 13, 2024 — BioNTech has reached an agreement to acquire Chinese biopharmaceutical company Biotheus for $800 million, a strategic move aimed at bolstering its oncology drug pipeline.

Details of the acquisition reveal that BioNTech, the German pharmaceutical company, will primarily pay in cash for the acquisition of Biotheus, which is based in Zhuhai. The deal also includes potential additional milestone payments that could reach up to $150 million.

This acquisition will grant BioNTech access to Biotheus's pipeline of drug candidates and its innovative bispecific antibody drug development platform, marking a significant expansion of BioNTech's footprint in China. Following the acquisition, Biotheus Zhuhai will be integrated as BioNTech's research and development hub in China, with over 300 Biotheus employees joining the BioNTech team.

As the angel investor in Biotheus since 2018, HLC has been a committed partner, supporting the company's development and growth and look forward to their continued success under the BioNTech platform as they work to advance next-generation therapeutics for patients worldwide.